Hybrid Nanomaterials for Drug Delivery

1st Edition - February 2, 2022
Editors: Prashant Kesharwani, N.K. Jain
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 8 5 7 5 4 - 3
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 0 3 5 6 - 1

Hybrid Nanomaterials for Drug Delivery covers a broad range of hybrid nanomaterials and nanocomposites used in drug delivery systems. The book reviews a variety of hybrid nanomater… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Hybrid Nanomaterials for Drug Delivery covers a broad range of hybrid nanomaterials and nanocomposites used in drug delivery systems. The book reviews a variety of hybrid nanomaterials and structures, including polymer-lipid, chitosan-based, protein-inorganic, quantum dot hybrids, and more. The strengths, limitations and regulatory aspects of hybrid drug delivery systems are also discussed, allowing readers to make informed decisions when choosing to utilize hybrid nanomaterials. Users will find this to be an exciting and comprehensive look into this emerging area. It will be of particular interest to academics and researchers working in materials science, engineering, biomedical engineering, nanotechnology and pharmaceutical science.

Multi nanocarrier-based hybrid systems are an emerging concept in the field of drug delivery that allow researchers to avoid some of the challenges faced when administering drugs, such as low bioavailability, development of drug resistance, toxicities, premature drug release, and therapeutic efficacy.

Cover image
Title page
Table of Contents
Copyright
Dedication
List of contributors
Preface
Acknowledgments
Chapter 1. Nanostructures and their associated challenges for drug delivery
Abstract
1.1 Introduction
1.2 Types of nanostructures for drug delivery
1.3 The main issues of nano drug delivery challenges
1.4 Conclusions and future perspectives
References
Chapter 2. Chemical and structural characterization of hybrid delivery systems studied by FTIR, NMR, and SAS techniques
Abstract
2.1 Introduction
2.2 Chemical and structural characterization techniques
2.3 Final considerations
Acknowledgment
References
Chapter 3. Applications of hybrid nanocrystals in drug delivery
Abstract
3.1 Introduction
3.2 The classification, composition, and characteristics of hybrid nanocrystals
3.3 Preparation methods of hybrid nanocrystals
3.4 Applications of hybrid nanocrystals in different administration routes
3.5 Conclusion
Acknowledgments
References
Chapter 4. Hybrid nanogel systems for drug delivery
Abstract
4.1 Introduction
4.2 The development of hybrid nanogels-based systems
4.3 Polymeric NPs-hydrogel nanocomposites
4.4 Metal NPs-hydrogel nanocomposites
4.5 pH responsive hybrid nanogel systems
4.6 Temperature responsive hybrid nanogel systems
4.7 Light-responsive hybrid nanogel systems
4.8 Magnetic-responsive hybrid nanogels systems
4.9 Conclusion and future perspectives
References
Chapter 5. Polymer–lipid hybrid nanostructures for drug delivery
Abstract
5.1 Introduction
5.2 Concept, structure, and mechanism of formation of polymer–lipid hybrid nanostructures
5.3 Types of polymer–lipid hybrid nanostructures
5.4 Preparation methodologies and formulation parameters
5.5 Advances in drug delivery using PLHNs
5.6 Conclusion and perspectives
References
Chapter 6. Hybrid chitosan-based nanoparticulate systems for drug delivery
Abstract
6.1 Introduction
6.2 Preparations of various hybrid chitosan
6.3 Hybrid chitosan for oral delivery
6.4 Hybrid chitosan for ocular delivery
6.5 Hybrid chitosan for pulmonary delivery
6.6 Applications of hybrid chitosan
6.7 Conclusion and future perspective
Acknowledgment
References
Chapter 7. Hybrid polymer−metal composites for drug delivery
Abstract
7.1 Introduction
7.2 Preparation methods of hybrid structures
7.3 Properties of hybrid structures
7.4 Potential application
7.5 Future prospective and conclusion
References
Chapter 8. Hybrid protein-inorganic nanoparticles for drug delivery in cancer therapy
Abstract
8.1 Introduction
8.2 Hybridization strategies
8.3 Drug loading
8.4 Protein corona
8.5 Impacts of protein functionalization
8.6 Pharmaceutical applications of hybrid protein-inorganic nanoparticles
8.7 Conclusion
References
Chapter 9. Silica−polymer hybrid nanoparticles for drug delivery and bioimaging
Abstract
9.1 Introduction
9.2 Surface modification of silica with polymers
9.3 Silica−polymer or silica−protein hybrid nanoparticles as diagnostics
9.4 Silica-polymer or protein hybrid nanoparticles as theranostics
9.5 Silica-polymer/protein hybrid nanoparticles as therapeutics
9.6 Conclusion
Acknowledgment
Conflict of interest
References
Chapter 10. Dendrimer nanohybrid systems for drug delivery
Abstract
10.1 Introduction
10.2 Dendrimers-based nanohybrid techniques
10.3 Advantages of dendrimer-based nanohybrids
10.4 Conclusion
References
Chapter 11. Bioactive hybrid nanowires for drug delivery
Abstract
11.1 Introduction
11.2 General properties of nanowires
11.3 Types of nanowires
11.4 Production methods for nanowires
11.5 Surface functionalization of nanowires (hybrid nanowires for biomaterials)
11.6 Bioapplications of nanowires
11.7 Toxicity of nanowires
11.8 Conclusions and future prospects
References
Chapter 12. Polymers and polymeric hybrids for targeted drug delivery
Abstract
12.1 Introduction
12.2 Principle for the design of anticancer nanomedicine
12.3 Polymers, polymeric conjugates, and polymeric micelles
12.4 Conclusions
References
Chapter 13. Quantum dots hybrid systems for drug delivery
Abstract
13.1 Introduction
13.2 Types of quantum dots
13.3 Synthesis of quantum dots
13.4 Surface modifications of quantum dots
13.5 Hybrid quantum dots for drug delivery
13.6 Conclusions
Acknowledgment
Competing interests
References
Chapter 14. Strengths, limitations, and regulatory aspects of hybrid drug delivery systems
Abstract
14.1 Introduction
14.2 Application/strength of hybrid drug delivery system
14.3 Hybrid drug delivery system as regulatory perspective
14.4 Requirement for hybrid drug marketing approvals
14.5 Hybrid pharmaceutical drugs
14.6 Few drugs that are appropriate for hybrid or 505(b)(2) mechanisms
14.7 Hybrid or 505(b)(2) versus generics
14.8 Selection criteria for drug candidate and hybrid system
14.9 Conclusion and future prospects
References
Chapter 15. Recent advances and future prospective of hybrid drug delivery systems
Abstract
15.1 Introduction
15.2 Importance of different hybrid system for drug delivery
15.3 Hybrid system to treat cancer
15.4 Recent development in hybrid drug delivery system
15.5 Conclusion
Acknowledgment
References
Index

Prashant Kesharwani

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.

Affiliations and expertise

Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

N.K. Jain

Prof. N.K. Jain is an internationally renowned academician and researcher and a senior professor in India who superannuated in June 2014 after rendering more than 40 years of dedicated and distinguished service as a teacher and 25 years as full professor. Prof. Jain is the author of two dozen celebrated books in pharmaceutical sciences in India and has contributed several chapters in national and international books. He has to his credit over 480 publications in reputed pharmaceutical Journals and has supervised 55 PhD and 141 M. Pharm. candidates. He has been a reviewer for several international and national research journals. Professor Jain’s current research interests include various aspects of controlled, novel and targeted drug delivery; nanotechnology and nanomedicine and he is globally known for his excellent research in the field of hydrotropic solubilization, resealed erythrocytes-based drug delivery and dendrimer drug delivery. Currently he is exploring the pharmaceutical potential of Carbon Nanotubes and Quantum Dots. Recently he has also contributed two chapters on international books.

Affiliations and expertise

Internationally Renowned Academician, Researcher and a Senior Professor, India

Life sciences

Physical sciences & Engineering

Social sciences & Humanities

Health